Accession Number:



EF5 PET of Tumor Hypoxia: A Predictive Imaging Biomarker of Response to Stereotactic Ablative Radiotherapy (SABR) for Early Lung Cancer

Descriptive Note:

Technical Report,15 Aug 2015,14 Sep 2016

Corporate Author:

Leland Stanford Junior University Stanford United States

Personal Author(s):

Report Date:


Pagination or Media Count:



Stereotactic ablative radiotherapy SABR has become a new standard of care for early stage lung cancer in patients who are not candidates for surgery because of excessive surgical risk, and will be an important treatment option for a growing segment of patients with lung cancer. This is particularly true as lung cancer screening efforts are expected to diagnose a greater proportion of lung cancers at earlier stages, yet the aging of the population will lead to a greater proportion of patients that increase surgical risk. Tumor hypoxia is a major known mechanism of radiation resistance and is especially expected to affect very short courses of radiation as in SABR. Imaging using a third generation hypoxia PET agent, 18F-EF5, is a promising approach for noninvasive hypoxia measurement that needs to be validated in the clinical setting.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement: